Literature DB >> 16579521

Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation.

Alejandro D Roth1, Gigliola Ramírez, Rodrigo Alarcón, Rommy Von Bernhardi.   

Abstract

Research on Alzheimer's disease (AD) focuses mainly on neuronal death and synaptic impairment induced by beta-Amyloid peptide (Abeta), events at least partially mediated by astrocyte and microglia activation. However, substantial white matter damage and its consequences on brain function warrant the study of oligodendrocytes participation in the pathogenesis and progression of AD. Here, we analyze reports on oligodendrocytes' compromise in AD and discuss some experimental data indicative of Abeta toxicity in culture. We observed that 1 microM of fibrilogenic Abeta peptide damages oligodendrocytes in vitro: while pro-inflammatory molecules (1 microg/ ml LPS + 1 ng/ml IFNgamma) or the presence of astrocytes reduced the Abeta-induced damage. This agrees with our previous results showing an astrocyte-mediated protective effect over Abeta-induced damage on hippocampal cells and modulation of the activation of microglial cells in culture. Oligodendrocytes protection by astrocytes could be, either by reduction of Abeta fibrilogenesis/deposition or prevention of oxidative damage. Likewise, the decrease of Abeta-induced damage by proinflammatory molecules could reflect the production of trophic factors by activated oligodendrocytes and/or a metabolic activation as observed during myelination. Considering the association of inflammation with neurodegenerative diseases. oligodendrocytes impairment in AD patients could potentiate cell damage under pathological conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16579521     DOI: 10.4067/s0716-97602005000400011

Source DB:  PubMed          Journal:  Biol Res        ISSN: 0716-9760            Impact factor:   5.612


  43 in total

Review 1.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.

Authors:  Tony Wyss-Coray; Joseph Rogers
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

2.  Decreased oligodendrocyte nuclear diameter in Alzheimer's disease and Lewy body dementia.

Authors:  Eva Gagyi; Bernadett Kormos; Karla J Castellanos; Klara Valyi-Nagy; Dennis Korneff; Patrizia LoPresti; Randy Woltjer; Tibor Valyi-Nagy
Journal:  Brain Pathol       Date:  2012-04-12       Impact factor: 6.508

3.  DTI studies in patients with Alzheimer's disease, mild cognitive impairment, or normal cognition with evaluation of the intrinsic background gradients.

Authors:  Geon-Ho Jahng; Songfan Xu; Micheal W Weiner; Dieter J Meyerhoff; Seungjoon Park; Norbert Schuff
Journal:  Neuroradiology       Date:  2011-02-22       Impact factor: 2.804

4.  OLIG2 over-expression impairs proliferation of human Down syndrome neural progenitors.

Authors:  Jie Lu; Gewei Lian; Hui Zhou; Giuseppe Esposito; Luca Steardo; Laurent C Delli-Bovi; Jonathan L Hecht; Q Richard Lu; Volney Sheen
Journal:  Hum Mol Genet       Date:  2012-02-17       Impact factor: 6.150

5.  Brain structure and cognitive correlates of body mass index in healthy older adults.

Authors:  Jacob D Bolzenius; David H Laidlaw; Ryan P Cabeen; Thomas E Conturo; Amanda R McMichael; Elizabeth M Lane; Jodi M Heaps; Lauren E Salminen; Laurie M Baker; Staci E Scott; Sarah A Cooley; John Gunstad; Robert H Paul
Journal:  Behav Brain Res       Date:  2014-10-22       Impact factor: 3.332

6.  Triple-transgenic Alzheimer's disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology.

Authors:  Maya K Desai; Kelly L Sudol; Michelle C Janelsins; Michael A Mastrangelo; Maria E Frazer; William J Bowers
Journal:  Glia       Date:  2009-01-01       Impact factor: 7.452

Review 7.  Glial cell dysregulation: a new perspective on Alzheimer disease.

Authors:  Rommy von Bernhardi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

Review 8.  Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells.

Authors:  Alison E Mungenast; Sandra Siegert; Li-Huei Tsai
Journal:  Mol Cell Neurosci       Date:  2015-12-04       Impact factor: 4.314

9.  Subcellular Changes in Bridging Integrator 1 Protein Expression in the Cerebral Cortex During the Progression of Alzheimer Disease Pathology.

Authors:  Stephanie L Adams; Kathy Tilton; James A Kozubek; Sudha Seshadri; Ivana Delalle
Journal:  J Neuropathol Exp Neurol       Date:  2016-06-26       Impact factor: 3.685

Review 10.  The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer's disease: Two sides of the same coin.

Authors:  Douglas G Peters; James R Connor; Mark D Meadowcroft
Journal:  Neurobiol Dis       Date:  2015-08-22       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.